MedPath

Validation of the REMINDER Dementia Risk Reduction Program

Not Applicable
Recruiting
Conditions
Healthy Aging
Risk Reduction
Old Age; Dementia
Interventions
Behavioral: REMINDER
Behavioral: Brain health Psychoeducation
Registration Number
NCT05296980
Lead Sponsor
University of Coimbra
Brief Summary

Until now, neuropsychological interventions aimed to optimize cognitive function and to have functional impact in individuals at risk of AD (MCI patients) were scarce in validity studies. While some RCTs have been developed in cognitive training interventions, comparative studies of merged interventions (cognitive, social and behavioral stimulation) with adequate control groups are absent, diminishing the professionals' trust on the adoption of these interventions for supporting patients. As such, the present proposal will develop a validation trial testing a multicomponent neuropsychological intervention (REMINDER), based on personal development, cognitive compensatory aids, meaningful goals setting, and behavior change techniques. The investigators will analyze its short/long-term gains and AD conversion rates. By aiming to provide a good validation study for REMINDER, the investigators will examine neurobiological, neurocognitive and functional outcomes of this intervention in comparison with an active control group (psychoeducation) in order to foster an effective outcome assessment of an intervention for individuals at risk of AD.

Detailed Description

The overarching tenet of this project is that, by providing a manualized multidomain intervention - REMINDER - that engages at risk individuals in the aims of this protocol, it can have a significant impact on health outcomes, optimizing healthier lifestyles and these being also understood along with the neurodegeneration signs of this impact.

The specific aims of this study will be:

* Recruit community-dwelling individuals with increased risk of dementia using CAIDE dementia risk score (with APOE, when available).

* Evaluate the REMINDER program (in comparison to an active control group (CT) - psychoeducation sessions) immediate effects regarding global cognition and functionality (primary outcomes) and neuropsychological, biochemical and neuroimaging outcomes (secondary outcomes).

* Determine the persistence of effects and begin characterizing the temporal course of putative benefits at 6-, and 18-months follow-up.

* Investigate the role of biomarkers (imaging and biochemical) in explaining the response to intervention and persistence of the effects and its correlation with neuropsychological and functionality measures.

* Measure the conversion rates from MCI to AD between the REMINDER and active control groups (at 24- months follow-up).

Our ultimate goal is to make available a scientifically validated and scalable intervention that helps prevent dementia in older adults at risk. By confirming the efficacy of REMINDER to prevent cognitive impairment and concluding for its medium-term efficacy to improve global cognitive function and healthy life habits the investigators are contributing to one of the WHO goals (Goal 3 - ensure healthy lives and promote well-being for all at all ages) by addressing risk reduction and management of a global health risk.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
400
Inclusion Criteria
  • Age 60 or older
  • CAIDE dementia risk score >8
  • Cognitive function: absence of significant cognitive impairment as per the Addenbrooke's Cognitive Examination-REVISED
  • Free of physical disabilities that preclude participation in the study
  • Willing to complete all study-related activities for 12 weeks
Exclusion Criteria
  • Mild cognitive impairment or dementia;
  • Presence of any neurological event in their medical history that could compromise actual cognition.
  • Presence of any severe psychiatric disorder (mild depressive and anxiety symptoms meet inclusion criteria).
  • Unability to travel to the site where the sessions will be delivered (if so randomization will be circumscribed between the experimental harm REMINDER online and the control group.
  • Illiteracy

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
REMINDER program onlineREMINDERThe REMINDER program in this arm will be delivered by videoconferencing. It will integrate 20 sessions (with approximate length of 45-60 min), therapist-mediated, carried out twice a week, over a period of 12 weeks. Psychoeducation sessions and part of the reminiscence and memory strategies training sessions will be facilitated in groups, as means to promote social support and modeling, and the remaining will be individual sessions. Several activities aimed to promote personal development and definition and achievement of meaningful goals will be included in the program, and the program will be manualized to facilitate its future dissemination and implementation
REMINDER program face-to-faceREMINDERThe REMINDER program in this arm will be delivered face to face. It will integrate 20 sessions (with approximate length of 45-60 min), therapist-mediated, carried out twice a week, over a period of 12 weeks. Psychoeducation sessions and part of the reminiscence and memory strategies training sessions will be facilitated in groups, as means to promote social support and modeling, and the remaining will be individual sessions. Several activities aimed to promote personal development and definition and achievement of meaningful goals will be included in the program, and the program will be manualized to facilitate its future dissemination and implementation
Brain psychoeducation programBrain health PsychoeducationThe control condition will have the same length as the experimental harms, including 20 psychoeducation sessions, with information regarding dementia modifiable risk factors, information on healthy lifestyles, and brain health promotion.
Primary Outcome Measures
NameTimeMethod
Blood biomarkers of neural damagePost intervention (1 week after the intervention sessions completion)

blood Neurofilament light chain (NfL) will be measured and tested as an outcome immediately after the intervention

Cognitive status compositeFollow - up (24 months after the intervention)

A composite score including the individual scores with Addenbrooke's Cognitive Examination - Revised (ACE-R), that includes the Mini Mental State Examination - MMSE (screening tools to consider eligibility), Subjective Cognitive Decline Questionnaire (SCDQ), Trail Making Test A and B (TMT A \& B), Verbal Fluency - Phonemic (P, M and R) and Categories (Animals), Stroop Test, Free and Cued Selective Reminding Test (FCSRT) will be generated to work as primary outcome

Functionality statusFollow - up (24 months after the intervention)

A composite score incorporating Adults and Older Adults Functional Assessment Inventory (IAFAI), University of California San Diego Performance-Based Skills Assessment (UPSA) will be used.

Secondary Outcome Measures
NameTimeMethod
Brain changesPost intervention (2 weeks after the intervention sessions completion)

hippocampus volume and DMN connectivity will be measured pre and post intervention in the RCT phase

Mood statusFollow-up (12 months after the intervention)

The Geriatric Depression Scale Short Form (GDS-15) (0-15, with higher scores meaning worse outcomes) and and The Geriatric Anxiety Inventory- Short Form (GAI-SF, 0-5, with higher scores meaning worse outcome) scores will be measured.

Perceived quality of lifeFollow-up (12 months after the intervention)

A measure of quality of life - World Health Organization Quality of Life - Old WHOQOL-OLD)will be incorporated to examine the effects of the program in self perceptions of well being. Higher scores mean better outcome

Perceived Self EfficacyFollow-up (12 months after the intervention)

A measure of self efficacy - Self Efficacy for Meaningful Activities (SEMActiv) will be implemented to examine self-efficacy, with higher scores meaning better outcome

Trial Locations

Locations (1)

Faculty of Psychology and Educational Sciences

🇵🇹

Coimbra, Portugal

© Copyright 2025. All Rights Reserved by MedPath